{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"26","value":"8"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"29","value":"4"}]}],"title":"Global health status (n=354, 309)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"27","value":"7"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"29","value":"5"}]}],"title":"Physical functioning (n=353, 318)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"26","value":"8"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"27","value":"4"}]}],"title":"Social functioning (n=352, 327)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"27","value":"7"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"26","value":"4"}]}],"title":"Motor dysfunction (n=361, 314)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"27","value":"8"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"24","value":"4"}]}],"title":"Communication deficit (n=365, 329)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"458"},{"groupId":"OG001","value":"463"}],"units":"Participants"}],"description":"EORTC QLQ-C30: 30 items; 5 functional scales; 9 symptom scales; \\& global health status. Most questions used 4-point scale (1:Not at all, 4:Very much), 2 questions used 7-point scale (1:very poor, 7:Excellent). EORTC QLQ-BN20: 20 items rated on a 4 point scale (1:not at all, 4:very much). EORTC QLQ-C30 and BN20 scores were transformed to a 0-100 scale, higher score=better functioning/global health (C30) or more severe symptoms (BN20). Stable HRQoL: change from baseline (BL) within 10 points. Improved HRQoL: an increase from BL \\>/=10 points for functioning/global health status, \\& decrease of \\>/=10 points for symptoms. PFS is reported for participants with Stable/Improved global health; physical, social functioning (C30); motor dysfunction \\& communication deficit (BN20). PFS: randomization to PD or death. PD: \\>=25% increase in sum of products of longest diameters of index lesions; or progression of existing non-index lesions; or appearance of new lesions; or neurological worsening.","dispersionType":"Full Range","groups":[{"description":"In the Concurrent Phase participants received radiotherapy (RT) in daily fractions of 2 Gray (Gy) given 5 days per weeks for 6 weeks (for a total of 60 Gy) and temozolomide 75 milligrams per square meter (mg/m\\^2) daily from the first day to the last day of radiotherapy (for a maximum of 49 days in case of delay to the end of radiation therapy) and bevacizumab (Avastin) 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of bevacizumab 10 mg/kg IV every 2 weeks and temozolomide 150 to 200 mg/m\\^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received bevacizumab 15 mg/kg IV every 3 weeks until disease progression/unacceptable toxicity. Participants then entered the last period: After Primary Overall Survival Analysis, in which participants were followed up for safety.","id":"OG000","title":"Bevacizumab + RT + Temozolomide"},{"description":"In the Concurrent Phase participants received radiotherapy in daily fractions of 2 Gy given 5 days per week for 6 weeks (for a total of 60 Gy) and temozolomide 75 mg/m\\^2 daily from the first day to the last day of radiotherapy (for a maximum of 49 days in case of delay to the end of radiation therapy) and placebo IV every 2 weeks for 6 weeks. There was a 4 week treatment break. Participants then entered the Maintenance Phase where they received six 28-day cycle of placebo IV every 2 weeks and temozolomide 150 to 200 mg/m\\^2 daily in the first 5 days of each cycle. The participants then entered the Monotherapy Phase where they received placebo IV every 3 weeks until disease progression/unacceptable toxicity. Participants then entered the last period: After Primary Overall Survival Analysis, in which participants were followed up for safety.","id":"OG001","title":"Placebo + RT + Temozolomide"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population. Number of Participants Analyzed = overall participants evaluable for this outcome measure; n = participants evaluable for specified category.","reportingStatus":"POSTED","timeFrame":"Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)","title":"PFS in Participants With Stable/Improved Health Related Quality of Life (HRQoL) Based on European Organization for Research & Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (C30)(EORTC QLQ-C30) & EORTC QLQ Brain Neoplasm 20 (BN20)","type":"SECONDARY","unitOfMeasure":"Months"}